Evidence map›Paper›PMID 41272611›Full record

SynthesisBMC cancer2025

Prenatal exposure to medication and risk of childhood cancer - a systematic review and meta-analysis.

Alicia Lübtow, Manuela Marron, Rajini Nagrani, Loviisa Mulanje, Wolfgang Ahrens, Lara Kim Brackmann

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alicia LübtowDepartment Epidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Manuela MarronDepartment Epidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Rajini NagraniDepartment Epidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Loviisa MulanjeDepartment Epidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Wolfgang AhrensDepartment Epidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Lara Kim BrackmannDepartment Epidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany. brackmann@leibniz-bips.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of medication during pregnancy carries a potential health risk, including childhood cancer, for the unborn child. However, most drugs examined in previous observational studies have shown inconsistent results with the risk of childhood cancer, and these findings have not been consolidated in drug-specific meta-analyses.

methodsWe conducted a systematic search in the databases PubMed and Web of Science for studies on medication use during pregnancy and childhood cancer risk. Studies with exposure to diethylstilbestrol as a known teratogen were excluded. Meta-analyses were conducted if ≥ 3 studies on the same research question were available to calculate pooled estimates for random effects models with 95% confidence intervals (CI). The I2 statistic was calculated to quantify between-study heterogeneity. Statistical significance of I2 was analyzed using Q statistic (P value for heterogeneity (P)). Study quality was assessed with a scoring tool adapted from the Newcastle–Ottawa Scale and ROBINS-E/I.

resultsOf 2,366 identified studies, 80 were included in the systematic review. Of these, 68 studies with a total of 14,396,922 participants were included in meta-analyses, covering 13 medication types and 11 childhood cancer sites across 70 analyses. From 54 site-specific analyses, we observed four risk reductions and eleven increases in risk. We found an increased risk for prenatal exposure to any kind of antibiotics and acute lymphoblastic leukemia (ALL; estimate (ES) = 1.14 (95%CI 1.03; 1.25), I2 = 19.1%, P = 0.26). For specific antibiotics, nitrosatable antibiotics were associated with an increased risk of childhood cancer overall (ES = 1.32 (1.13; 1.55), I2 = 0.0%, P = 0.98). Maternal intake of vitamin and mineral supplements was associated with a reduced risk of acute leukemia (AL) (ES = 0.72 (0.54; 0.96), I2=46.3%, P = 0.16), ALL (ES = 0.81 (0.67; 0.99), I2 = 66.6%, P = 0.001) and tumors of the central nervous system (CNS; ES = 0.77 (0.62; 0.96), I2 = 67.2%, P = 0.002). DISCUSSION: Our results suggest that the use of antibiotics during pregnancy was associated with an increased childhood cancer risk, although this association is likely influenced by the underlying maternal infections that required treatment. This highlights the importance of considering maternal health factors when interpreting medication–related associations. Supplementation of vitamins and minerals during pregnancy might decrease the risk of AL, ALL and CNS tumors in children.

Indexed as

NeoplasmsPrenatal Exposure Delayed EffectsChildFemaleHumansPregnancyRisk FactorsAntibioticsLeukemiaMalignancyNeoplasmsPharmaceutical preparationsPregnancy

Identifiers

PMID41272611
PMCPMC12667062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.